ClinicalTrials.Veeva

Menu

Yervoy Pregnancy Surveillance Study

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status

Withdrawn

Conditions

Melanoma

Treatments

Drug: Yervoy

Study type

Observational

Funder types

Industry

Identifiers

NCT02854488
CA184-487

Details and patient eligibility

About

The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age

Sex

Female

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment

Exclusion criteria

  • Women whose ipilimumab exposure is outside the window of pregnancy exposure
  • Pregnancies for which there is only paternal exposure to Yervoy

Other protocol defined inclusion/exclusion criteria could apply

Trial design

0 participants in 1 patient group

Women Exposed to Yervoy (ipilimumab) During Pregnancy
Description:
Women Exposed to Yervoy (ipilimumab) During Pregnancy and the Children from These Pregnancies
Treatment:
Drug: Yervoy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems